Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory approvals) across these markets.

·      Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.

·      Ryaltris™, developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate), indicated for treatment of symptoms associated with allergic rhinitis (AR) in adults and pediatric patients, 12 years of age and older.

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global, integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Lotus International Pte. Ltd., a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Lotus), for commercializing its innovative nasal spray Ryaltris™ in Singapore, Hong Kong and Vietnam.